These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12660500)

  • 21. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
    Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus.
    Servais A; Meas-Yedid V; Toupance O; Lebranchu Y; Thierry A; Moulin B; Etienne I; Presne C; Hurault de LB; Le Pogamp P; Le Meur Y; Glotz D; Hayem C; Olivo Marin JC; Thervet E
    Am J Transplant; 2009 Nov; 9(11):2552-60. PubMed ID: 19843033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TGF-β1 expression in kidney allograft protocol biopsies during cyclosporine A therapy.
    Ortiz F; Helanterä IT; Räisänen-Sokolowski A; Honkanen EO; Koskinen PK
    Int J Artif Organs; 2013 Jan; 36(1):56-62. PubMed ID: 23280075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
    J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli.
    Esposito C; Foschi A; Parrilla B; Cornacchia F; Fasoli G; Plati AR; De Mauri A; Mazzullo T; Scudellaro R; Dal Canton A
    Transplant Proc; 2004 Apr; 36(3):695-7. PubMed ID: 15110634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings.
    Gotti E; Perico N; Perna A; Gaspari F; Cattaneo D; Caruso R; Ferrari S; Stucchi N; Marchetti G; Abbate M; Remuzzi G
    J Am Soc Nephrol; 2003 Mar; 14(3):755-66. PubMed ID: 12595513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
    Baczkowska T; Perkowska-Ptasińska A; Sadowska A; Lewandowski Z; Nowacka-Cieciura E; Cieciura T; Pazik J; Lewandowska D; Mroz A; Urbanowicz A; Nazarewski S; Danielewicz R
    Transplant Proc; 2005 Mar; 37(2):773-5. PubMed ID: 15848527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TGF-beta1 expression in renal allograft rejection and cyclosporine A toxicity.
    Ozdemir BH; Ozdemir FN; Demirhan B; Haberal M
    Transplantation; 2005 Dec; 80(12):1681-5. PubMed ID: 16378061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study.
    Stoves J; Newstead CG
    Transplantation; 2002 Dec; 74(12):1794-7. PubMed ID: 12499901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Goldfarb DA
    J Urol; 2005 Jun; 173(6):2106-7. PubMed ID: 15879857
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effects of atorvastatin on chronic allograft nephropathy in rats.
    Zhang W; Liu M; Wu Y; Zhu P; Yin C; Zhang W; Gu M
    J Surg Res; 2007 Dec; 143(2):428-36. PubMed ID: 17628598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.